A biotech with plans to make an oral drug that has the same target as Humira, formerly the world’s top-selling medicine, has raised $47.5 million
Since Takeda paid billions for Nimbus Therapeutics’ program in 2022, TYK2 has been one of immunology’s hottest targets. But it’s also crowded, with biotechs herding
D3 Bio has secured $108 million in a Series B fundraise, with the main goal of advancing its lead drug candidate targeting KRAS-G12C into global
With two cancer drugs in clinical testing, BlossomHill Therapeutics has convinced investors to fuel the San Diego startup with another $84 million in its attempt
Fondazione Telethon’s Waskyra has become the first gene therapy in the US for Wiskott-Aldrich syndrome, and the first taken to market by a non-profit.
The UK government’s drug rebate tax will fall to 14.5% for new drugs next year, down from nearly 23%, according to new details following the UK-US trade deal revealed last week.
But the payment rates …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844